The Five-Year Prospective Study of Quality of Life in Hemifacial Spasm Treated with Abo-Botulinum Toxin A.

Toxins (Basel) · 2021 · PMC7999068 · PMID 33809486

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

borderline significantp = 0.055so close (0.05 < p ≤ 0.1)

Interestingly, the bodily pain domain showed borderline significant ( p = 0.055) reduction of pain score at second year of treatment.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.